Compare STKS & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKS | SERA |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 75.2M |
| IPO Year | 2011 | 2021 |
| Metric | STKS | SERA |
|---|---|---|
| Price | $1.78 | $2.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.70 | N/A |
| AVG Volume (30 Days) | 28.6K | ★ 62.4K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $805,722,000.00 | $81,000.00 |
| Revenue This Year | $7.47 | $554.81 |
| Revenue Next Year | $8.12 | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.66 | 5.19 |
| 52 Week Low | $1.65 | $1.37 |
| 52 Week High | $5.19 | $4.09 |
| Indicator | STKS | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 61.45 |
| Support Level | $1.67 | $1.67 |
| Resistance Level | $2.06 | $2.40 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 27.63 | 84.63 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.